Quick Answer
CERO THERAPEUTICS HOLDINGS, INC. reported Research And Development Expense of $6.32 million for the year ending 2024.
- CERO THERAPEUTICS HOLDINGS, INC. showed an increase of +726.4% in Research And Development Expense from 2024 to 2024.
- This data is from CERO THERAPEUTICS HOLDINGS, INC.'s annual report (Form 10-K), filed with the SEC on April 15, 2025.
- XBRL data for this metric is available from 2023 to 2024 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: $1.80 million | Q2 2023: $1.19 million | Q1 2024: $764.2 thousand | Q1 2024: $904.0 thousand | Q2 2024: $2.71 million | Q3 2024: $1.77 million | Q1 2025: $2.91 million | Q2 2025: $2.75 million | Q3 2025: $2.39 million.
- Over the full 3 years of available data (2023 to 2024), CERO THERAPEUTICS HOLDINGS, INC.'s Research And Development Expense has grown by 19.4%.
- Historical annual values: Fiscal year 2024: $6.32 million | Fiscal year 2024: $764.2 thousand | Fiscal year 2023: $5.29 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: